204 related articles for article (PubMed ID: 2940212)
1. Cephalosporins, vancomycin, aminoglycosides and other drugs, especially in combination, for the treatment of methicillin-resistant staphylococcal infections.
Klastersky J; Van der Auwera P
J Antimicrob Chemother; 1986 Mar; 17 Suppl A():19-24. PubMed ID: 2940212
[TBL] [Abstract][Full Text] [Related]
2. In vitro susceptibility of methicillin-resistant Staphylococcus aureus to imipenem and other antimicrobial agents.
Ishag AJ; Durgham SM; Shibl AM
Chemioterapia; 1987 Aug; 6(4):261-3. PubMed ID: 3477333
[TBL] [Abstract][Full Text] [Related]
3. Treatment of infections due to methicillin-resistant Staphylococcus aureus.
Waldvogel FA
J Hosp Infect; 1986 Mar; 7 Suppl A():37-46. PubMed ID: 2871096
[No Abstract] [Full Text] [Related]
4. In vitro activity of fosfomycin combined with rifampin, pefloxacin and imipenem against staphylococci: a study by the time-kill curve method.
Quentin C; Saivin S; Lafferriere C; Noury P; Bebear C
Drugs Exp Clin Res; 1987; 13(4):219-24. PubMed ID: 3476291
[TBL] [Abstract][Full Text] [Related]
5. Update on prevalence and treatment of methicillin-resistant Staphylococcus aureus infections.
Loffler CA; Macdougall C
Expert Rev Anti Infect Ther; 2007 Dec; 5(6):961-81. PubMed ID: 18039081
[TBL] [Abstract][Full Text] [Related]
6. Teicoplanin, vancomycin, rifampicin: in-vivo and in-vitro studies with Staphylococcus aureus.
Carper HT; Sullivan GW; Mandell GL
J Antimicrob Chemother; 1987 May; 19(5):659-62. PubMed ID: 2956229
[TBL] [Abstract][Full Text] [Related]
7. In vitro combined bactericidal activity of cefpirome and glycopeptides against glycopeptides and oxacillin-resistant staphylococci.
Bergeret M; Boutros N; Raymond J
Int J Antimicrob Agents; 2004 Mar; 23(3):247-53. PubMed ID: 15164965
[TBL] [Abstract][Full Text] [Related]
8. In vitro study of the potential role of quinupristin/dalfopristin in the treatment of catheter-related staphylococcal infections.
Garcia R; Raad I
Eur J Clin Microbiol Infect Dis; 1996 Dec; 15(12):933-6. PubMed ID: 9031876
[TBL] [Abstract][Full Text] [Related]
9. In vitro evaluation of antibiotics' combinations for empirical therapy of suspected methicillin resistant Staphylococcus aureus severe respiratory infections.
Drago L; De Vecchi E; Nicola L; Gismondo MR
BMC Infect Dis; 2007 Sep; 7():111. PubMed ID: 17888153
[TBL] [Abstract][Full Text] [Related]
10. Activity of teicoplanin in localized experimental infections in rats.
Arioli V; Berti M; Candiani G
J Hosp Infect; 1986 Mar; 7 Suppl A():91-9. PubMed ID: 2871103
[TBL] [Abstract][Full Text] [Related]
11. Antistaphylococcal activity of teicoplanin in Riyadh, Saudi Arabia.
Shibl AM; Ishag AH; Durgham SM
APMIS Suppl; 1988; 3():68-70. PubMed ID: 2972301
[TBL] [Abstract][Full Text] [Related]
12. Teicoplanin compared with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus epidermidis.
Galetto DW; Boscia JA; Kobasa WD; Kaye D
J Infect Dis; 1986 Jul; 154(1):69-75. PubMed ID: 2940303
[TBL] [Abstract][Full Text] [Related]
13. Vancomycin therapy of severe staphylococcal infections.
Kirby WM
J Antimicrob Chemother; 1984 Dec; 14 Suppl D():73-8. PubMed ID: 6394579
[TBL] [Abstract][Full Text] [Related]
14. [Methicillin resistant staphylococci].
Afanas'eva TI
Antibiot Khimioter; 1998; 43(6):29-31. PubMed ID: 9644532
[No Abstract] [Full Text] [Related]
15. Anti-staphylococcal activity of teicoplanin, vancomycin, and other antimicrobial agents: the significance of methicillin resistance.
Del Bene VE; John JF; Twitty JA; Lewis JW
J Infect Dis; 1986 Aug; 154(2):349-52. PubMed ID: 2941491
[No Abstract] [Full Text] [Related]
16. Emergence and spread of rifampicin-resistant, methicillin-resistant Staphylococcus aureus during vancomycin-rifampicin combination therapy in an intensive care unit.
Ju O; Woolley M; Gordon D
Eur J Clin Microbiol Infect Dis; 2006 Jan; 25(1):61-2. PubMed ID: 16331332
[No Abstract] [Full Text] [Related]
17. Treatment of infections due to methicillin-resistant Staphylococcus aureus.
Watanakunakorn C
Ann Intern Med; 1982 Sep; 97(3):376-8. PubMed ID: 7114635
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study.
Karlowsky JA; Adam HJ; Poutanen SM; Hoban DJ; Zhanel GG;
Diagn Microbiol Infect Dis; 2011 Mar; 69(3):342-7. PubMed ID: 21353963
[TBL] [Abstract][Full Text] [Related]
19. Bactericidal activity of oxacillin and glycopeptides against Staphylococcus aureus in patients with endocarditis: looking for a relationship between tolerance and outcome.
Pasticci MB; Moretti A; Stagni G; Ravasio V; Soavi L; Raglio A; Vailati F; Cardaccia A; Santucci A; Papili R; Sgrelli A; Pallotto C; Baldelli F
Ann Clin Microbiol Antimicrob; 2011 Jun; 10():26. PubMed ID: 21658248
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy of pefloxacin and six other antimicrobial agents on Staphylococcus aureus experimental abscesses.
Rolin O; Huet Y; Bouanchaud DH
J Antimicrob Chemother; 1986 Apr; 17 Suppl B():49-52. PubMed ID: 2940215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
